Pharmaceutical - Antibiotics and Infectious diseases

Filter

Popular Filters

126 to 150 of 226 results

Hikma licenses Vibativ from Theravance for MENA region

02-07-2013

Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) says it has signed an exclusive commercialization…

Antibiotics and Infectious diseasesHikma PharmaceuticalsLicensingPharmaceuticalRest of the WorldTheravanceVibativ

US FDA puts clinical hold on Achillion's sovaprevir on safety concerns

02-07-2013

USA-based Achillion Pharmaceuticals (Nasdaq: ACHN) announced yesterday (July 1) that the US Food and…

Achillion PharmaceuticalsAntibiotics and Infectious diseasesatazanivirPharmaceuticalRegulationsovaprevir

India must address worrying stock out of tuberculosis drugs, says MSF

24-06-2013

The Indian government must urgently address the persistent issues and almost routine delays of procuring…

Antibiotics and Infectious diseasesAsia-PacificHealthcareMarkets & MarketingPharmaceuticalPolitics

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds

20-06-2013

Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Rising drug resistance driving early-line use of powerful antibiotics, according to surveyed EU5 physicians

13-06-2013

More than half of physicians surveyed by health care advisory firm, Decision Resources from the EU5 (France,…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceutical

Ferrer's Ozenoxacin shows superiority in Ph III impetigo trial

05-06-2013

Privately-held Spanish drugmaker Ferrer Internacional says that it has successfully completed a Phase…

Antibiotics and Infectious diseasesDermatologicalsFerrer InternacionalLicensingOzenoxacinPharmaceuticalResearch

UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products

30-05-2013

UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

Merck & Co returns antifungal MK-3118 rights to Scynexis

29-05-2013

US venture capital backed drug developer Scynexis says that pharma giant Merck & Co has decided to return…

Antibiotics and Infectious diseasesLicensingMerck & CoMK-3118PharmaceuticalScynexis

Grifols gains global rights to Aradigm's Pulmaquin

23-05-2013

Spanish drugmaker Grifols (GRLS: MC) has signed an exclusive, worldwide license for USA-based Aradigm's…

Antibiotics and Infectious diseasesAradigmCiprofloxacinGrifolsLicensingMergers & AcquisitionsPharmaceuticalPulmaquinRespiratory and Pulmonary

GlaxoSmithKline gets $200 million BARDA award to develop new antibiotics

22-05-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and the Biomedical Advanced Research and Development Authority…

Antibiotics and Infectious diseasesFinancialGlaxoSmithKlinePharmaceuticalResearch

Novo A/S acquires Norway's Xellia Pharmaceuticals in $700 million deal

21-05-2013

Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in Novo Nordisk…

Antibiotics and Infectious diseasesGenericsMergers & AcquisitionsNovo A/SNovo NordiskPharmaceuticalXellia Pharmaceuticals

Infectious disease treatments market driven by growth in middle-income to low-income countries

17-05-2013

The infectious disease treatments market increased at a compound annual growth rate (CAGR) of 6.9% between…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalVaccines

Cempra out-licenses solithromycin to Toyama Chemical in Japan

15-05-2013

USA-based clinical-stage antibiotics developer Cempra (Nasdaq: CEMP) has signed an exclusive license…

Antibiotics and Infectious diseasesAsia-PacificCempraLicensingPharmaceuticalsolithromycinToyama

Shire's ADHA drug Elvanse accepted for NHS use in Scotland; UK guidance on fidaxomicin

14-05-2013

Ireland-headquartered Shire plc (LSE: SHP) said yesterday (May 13) that its single-daily dose long-acting…

Antibiotics and Infectious diseasesAstellas PharmaDificlirElvanseEuropefidaxomicinNeurologicalPharmaceuticalRegulationShire

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone

02-05-2013

US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

Soligenix and Intrexon collaborate on Melioidosis therapy development

01-05-2013

US clinical stage biopharma company Soligenix (OTCBB: SNGX) says it will jointly develop a treatment…

Antibiotics and Infectious diseasesBiotechnologyIntrexonLicensingPharmaceuticalResearchSoligenix

IQWiG finds no added proven benefit for Astellas' fidaxomicin in Clostridium difficile infection

23-04-2013

In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirfidaxomicinPharmaceuticalPricingRegulation

New European anti-infectives company, Allecra Therapeutics, created

18-04-2013

The creation of Allecra Therapeutics, a new company joining the established European BioValley Life Sciences…

Allecra TherapeuticsAntibiotics and Infectious diseasesFinancialOrchid Chemicals & PharmaceuticalsPharmaceuticalResearch

Breakthrough status for Pfizer's palbociclib; Merck & Co Noxafil NDA accepted

11-04-2013

Global pharma behemoth Pfizer (NYSE: PFE) is the latest to gain a "Breakthrough Therapy" designation…

Antibiotics and Infectious diseasesMerck & CoNorth AmericaNoxafilOncologypalbociclibPfizerPharmaceuticalRegulation

126 to 150 of 226 results

Back to top